ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $982,000 | -30.5% | 27,551 | -10.0% | 0.00% | -33.3% |
| Q2 2023 | $1,412,000 | -36.4% | 30,602 | -44.7% | 0.01% | -33.3% |
| Q1 2023 | $2,219,000 | -15.0% | 55,345 | -1.8% | 0.01% | -18.2% |
| Q4 2022 | $2,612,000 | +66.7% | 56,376 | +48.9% | 0.01% | +57.1% |
| Q3 2022 | $1,567,000 | -21.0% | 37,851 | +13.8% | 0.01% | -12.5% |
| Q2 2022 | $1,984,000 | -24.2% | 33,247 | -7.7% | 0.01% | -11.1% |
| Q1 2022 | $2,616,000 | -16.5% | 36,023 | -3.3% | 0.01% | -18.2% |
| Q4 2021 | $3,133,000 | -8.6% | 37,252 | -1.9% | 0.01% | -8.3% |
| Q3 2021 | $3,426,000 | -6.1% | 37,986 | -0.8% | 0.01% | -7.7% |
| Q2 2021 | $3,650,000 | +2544.9% | 38,276 | +3063.3% | 0.01% | +1200.0% |
| Q1 2021 | $138,000 | -17.9% | 1,210 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $168,000 | +50.0% | 1,210 | -11.5% | 0.00% | 0.0% |
| Q3 2020 | $112,000 | – | 1,368 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |